1
/
of
1
Elabscience
SKU:PKSH033932
Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 2/ LAIR2/CD306 (C-Fc)
Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 2/ LAIR2/CD306 (C-Fc)
Regular price
$200.00 USD
Regular price
Sale price
$200.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 2/LAIR2/CD306 (C-Fc), a cutting-edge product meticulously designed to revolutionize the field of immunology. This innovative offering showcases a fusion protein that combines the remarkable attributes of the Leukocyte-associated Immunoglobulin-like Receptor 2 (LAIR2) and CD306, resulting in an unparalleled solution for immunological research and therapeutic applications.
Crafted with utmost precision, this recombinant protein exhibits exceptional purity and stability, ensuring optimal performance in a wide array of experimental settings. Its unique composition enables the investigation of intricate immunological processes, shedding light on the complex interplay between immune cells and their microenvironment.
The Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 2/LAIR2/CD306 (C-Fc) boasts an extensive range of applications, including but not limited to, elucidating the role of LAIR2 and CD306 in immune regulation, deciphering their involvement in disease pathogenesis, and facilitating the development of novel therapeutic strategies. Its versatility empowers researchers and clinicians alike to delve into the intricacies of immune responses, paving the way for groundbreaking discoveries and advancements in the field.
This exceptional product is meticulously manufactured in state-of-the-art facilities, adhering to stringent quality control measures to ensure utmost reliability and reproducibility. Each batch undergoes rigorous testing, guaranteeing consistent performance and delivering results of the highest caliber.
In summary, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 2/LAIR2/CD306 (C-Fc) represents a pinnacle of scientific innovation, offering an unrivaled tool for immunological research and therapeutic exploration. With its remarkable attributes, this fusion protein is poised to revolutionize the understanding of immune regulation and disease pathogenesis, propelling the field towards new horizons of knowledge and therapeutic possibilities.
Crafted with utmost precision, this recombinant protein exhibits exceptional purity and stability, ensuring optimal performance in a wide array of experimental settings. Its unique composition enables the investigation of intricate immunological processes, shedding light on the complex interplay between immune cells and their microenvironment.
The Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 2/LAIR2/CD306 (C-Fc) boasts an extensive range of applications, including but not limited to, elucidating the role of LAIR2 and CD306 in immune regulation, deciphering their involvement in disease pathogenesis, and facilitating the development of novel therapeutic strategies. Its versatility empowers researchers and clinicians alike to delve into the intricacies of immune responses, paving the way for groundbreaking discoveries and advancements in the field.
This exceptional product is meticulously manufactured in state-of-the-art facilities, adhering to stringent quality control measures to ensure utmost reliability and reproducibility. Each batch undergoes rigorous testing, guaranteeing consistent performance and delivering results of the highest caliber.
In summary, the Recombinant Human Leukocyte-associated Immunoglobulin-like Receptor 2/LAIR2/CD306 (C-Fc) represents a pinnacle of scientific innovation, offering an unrivaled tool for immunological research and therapeutic exploration. With its remarkable attributes, this fusion protein is poised to revolutionize the understanding of immune regulation and disease pathogenesis, propelling the field towards new horizons of knowledge and therapeutic possibilities.
Share
